DoW Breast Cancer, Clinical Research Extension Award
About
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Distinctive Features: · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
The DoW Breast Cancer, Clinical Research Extension Award supports researchers who are extending the impact of existing breast cancer clinical studies. This grant mechanism is designed for research teams committed to maximizing the value of patient participation by extending data collection, follow-up periods, and analysis of ongoing or recently concluded clinical trials. The award addresses critical gaps that often occur due to early trial termination, insufficient patient follow-up, or incomplete sample and data collection. This is an ideal funding opportunity for clinical researchers, oncologists, and research institutions working to strengthen the evidence base for breast cancer treatment and care. The program requires multidisciplinary teams that include at least two breast cancer consumer advocates, ensuring patient perspectives shape the research direction. Whether you're looking to extend a trial that ended prematurely, deepen follow-up with existing patient cohorts, or enhance data analysis from completed studies, this award provides the resources to unlock clinically relevant insights that directly benefit breast cancer patients. The flexible leadership structure—allowing either a single Principal Investigator or two partnering PIs—accommodates various institutional arrangements and collaborative research models.
Funding Facts
● Applications openDeadline
July 8, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle
Deadline
2026-07-08
Grant Type
federal
Application Cycle
Annual (FY2026 deadline: July 8, 2026)
Best For
Clinical researchers, academic institutions, and research teams extending breast cancer clinical trials with multidisciplinary expertise and consumer advocate involvement
Frequently Asked Questions
Who is eligible for DoW Breast Cancer, Clinical Research Extension Award?
Specific eligibility criteria are not detailed in the available information. However, applicants should note that research teams must include at least two breast cancer consumer advocates. The program supports both single PI and dual PI (Initiating PI and Partnering PI) structures. For complete eligibility requirements, including institutional eligibility, funding caps, and specific qualification criteria, please visit the official Department of Defense (DoD) Breast Cancer Research Program website or contact the program directly.
How much funding does DoW Breast Cancer, Clinical Research Extension Award provide?
The specific funding amount or range is not provided in the available program information. Award amounts typically vary by cycle and project scope. Contact the Department of Defense Breast Cancer Research Program or visit their official website for current funding levels for the FY2026 cycle.
How do I apply for DoW Breast Cancer, Clinical Research Extension Award?
The application process includes a two-stage submission: (1) Initiating PI(s) submit a pre-application, and (2) at the full application stage, both Initiating PI and Partnering PI (if applicable) must submit complete applications by the deadline. All applications must address at least one FY2026 BCRP overarching challenge or provide adequate justification for exception. Note that failure to submit all required applications by the deadline may result in administrative withdrawal. For detailed instructions, submission portals, and specific requirements, visit the official DoD Breast Cancer Research Program website.
What can DoW Breast Cancer, Clinical Research Extension Award funding be used for?
This award funds research that extends data collection, follow-up, and analysis of existing breast cancer clinical studies. It is specifically designed to address knowledge gaps resulting from early trial termination, limited patient follow-up, or suboptimal sample and data collection and analysis. Funding supports extending the clinical relevance and impact of breast cancer patient participation in established studies.
Last updated: July 5, 2026